期刊文献+

人骨肉瘤耐药细胞系MG-63/PTX的建立及多药耐药机制研究 被引量:1

A study of establishment of multidrug resistant cell line MG-63/PTX in human osteosarcoma and the mechanism of multidrug resistance
原文传递
导出
摘要 目的建立人骨肉瘤细胞多药耐药亚系,探讨骨肉瘤细胞多药耐药的发生机制。方法采用紫杉醇大剂量间断冲击培养法,诱导建立紫杉醇耐药骨肉瘤细胞系(MG-63/PTX),并运用MTT法检测6种药物敏感性变化及细胞生长规律变化,流式细胞仪分析亲本细胞系和耐药细胞系的细胞膜表面P-gp蛋白表达率、罗丹明123排出情况,RT-PCR检测细胞内耐药基因的变化,免疫细胞化学法检测细胞内P-gp蛋白的表达,Westernblotting法检测细胞内P-gp蛋白的表达。结果历时12个月建成人骨肉瘤耐药细胞系MG-63/PTX,能在含PTX1μg/mL的培养基中稳定生长并传代,其对PTX的耐药指数为69.8,并与卡铂、顺铂、表柔比星、甲氨蝶呤、阿霉素等多种化疗药物存在不同程度的交叉耐药性;罗丹明123排出实验显示MG-63/PTX内罗丹明含量明显低于亲本细胞;RT-PCR结果显示在MG-63/PTX细胞系中存在MDR1、MRP1、LRP、ABCG2基因的表达,而在MG-63细胞系中无MDR1基因的表达。免疫细胞化学、流式细胞仪及Western blotting实验均显示在MG-63/PTX中存在P-gp的表达。结论 MDR1/P-gp在多药耐药的特性上起着至关重要的作用,而且骨肉瘤多药耐药细胞亚系为进一步研究骨肉瘤耐药特征及逆转方法打下基础。 Objective To explore the pathogenesis of multidrug resistance of osteosarcoma through establishing multidrng-resistant cell line subpopulation of human osteosarcoma. Methods Paclitaxel discontinuous impact culture method of high-dose was conducted to induce the development of paclitaxel drug-resistant cell line MG-63/PTX of osteosarcoma. 3- (4,5-Dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide (MTT) was used to test the change of drug susceptibility and law of cell growth of 6 medications. Flow cytometry was used to analyze the expression rate of human permeability glycoprotein (P-gp) on the surface of cell membrane of parent cell line and drug-resistant cell line and the eduction of rhodamine123. Reverse transcription-polymerase chain reaction (RT-PCR) was used to exam the change of drug-resistant gene in cells. Immunocytochemistry was applied to exam the expression of P-gp in cells. Western blotting was conducted to exam the expression of P-gp in cells. Results Drug-resistant cell line MG-63/PTX of human osteosarcoma was successfully established after 12 month, and it could grow stably and go down to the future generation in the culture medium with 1ug / ml plataxel. Regarding plataxel, the drug-resistant index of cell line MG-63/PTX was 69.8, and it exhibited cross-resistance to many other chemotherapeutic agents such as carboplatin, cisplatin, epirubicin, methotrexate and adriamycin etc to different degrees. From the eduction of rhodamine, it was showed that the content of rhodamine in cell line MG-63/PTX was obvious lower than the parent cell line. The results of RT-PCR showed that the expressions of MDR1, MRP1, LRP and ABCG2 exists in the cell line MG-63/ PTX. MDR1 was not expressed in cell line MG-63. P-gp expression existed in cell line MG-63/PTX through the test of immunohistochemical, flow cytometry and western blotting. Conclusions MDR1/P-gp may play a crucial role in the characteristics of multidrug resistance. Multidrug-resistant cell line subselies in human osteosarcoma provide the basis for future research of characteristics of multidrug resistance in osteosarcoma and technique of reverse.
出处 《中国骨肿瘤骨病》 2011年第3期270-276,共7页 Chinse Journal Of Bone Tumor And Bone Disease
基金 国家自然科学基金重点项目(30330610) 国家自然科学基金面上项目(30873027) 陕西省科学技术研究发展计划项目(2010K13-02-05)
关键词 骨肉瘤 耐药细胞系 多药耐药 Ostetosarcoma Drug-resistant cell line Multidrug resistance
  • 相关文献

参考文献3

二级参考文献26

  • 1[1]Michael Colvin:Drug Resistance in the Treatment of Sarcomas. Seminars in Oncology, 1997,24: 580 - 591.
  • 2[2]Nicola Baldini, et al. Expression of P - glycoprotein in high - grade osteosarcomas in relation to clinical outcome. The New England Journal of Medicine, 1995,23:1380 - 1385.
  • 3[3]Wyman JJ, et al. Multidrug resistance- 1 and p- glycoprotein in human chondrosarcoma cell lines: expression correlates with decreased intracellular doxorubicin and in vitro chemoresistance.J Orthop Res, 1999,17:935-940.
  • 4[4]Litman T, Druley TE, Stein WD, et al. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci,2001,58:931 -959.
  • 5[5]Sonneveld P. Multidrug resistance in haematological malignancies. J Intern Med,2000,247:521 - 534.
  • 6[6]Tan B, Piwnica - Worms D, Ratner L. Multidrug resistance transporters and modulation. Curr Opin Oncol,2000,12:450 - 458.
  • 7[7]Wei Guo, et al. Mechanisms of Methotrexate Resistance in Osteosarcoma.Clinical Cancer Research, 1999,5:621 - 627.
  • 8[8]J.R. Bertino et al. Resistance Mechanisms to Methotrexate in Tumors.STEM CELLS, 1996,14: 5 - 9.
  • 9[9]Richard Gorlick, et al. Intrinsic and acquired resistance to methotrexate in acute leukemia. The New England Journal of Medicine, 1996,335:1041 -1048(October3).
  • 10[10]William H. Meyer, et al. Accumulation, Intracellular Metabolism, and Antitumor Activity of High - and Low - Dose Methotrexate in Human Osteosarcoma Xenografts. Cancer Communications, 1990,2: 219 - 229.

共引文献19

同被引文献7

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部